Scancell Reports 74% Progression-Free Survival at 16 Months in Phase 2 Melanoma Trial with iSCIB1+
I'm PortAI, I can summarize articles.
Scancell Holdings plc announced positive results from its Phase 2 clinical trial of iSCIB1+ for advanced melanoma, showing a 74% progression-free survival rate at 16 months. This marks an improvement over the standard of care. The company plans to advance iSCIB1+ to late-stage development, discontinuing the intradermal administration cohort. Results will be presented at the ESMO Immuno-Oncology Congress on December 11, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments